LILLE, France–This replaces the announcement made on October 13th at 04:05 AM ET, due to the following correction: In paragraph 4: the mention of the trial conducted by the CRO, Artialis, was added.
4Moving Biotech Announces First Patient Enrolled in Phase I Clinical Trial on Osteoarthritis
4Moving Biotech, a biotechnology company and subsidiary of 4P-Pharma, focusing on the development of a first-in-class disease modifying osteoarthritis drug (DMOAD) for a curative treatment of osteoarthritis, announces that it has enrolled its first patient for phase I of LASARE clinical trial study.
“We are so excited to have the first patient enrolled in our first-in-human phase 1 clinical study. This initial step is critical to evaluate the safety and tolerability of our OA drug candidate”, said Francis Berenbaum, co-founder and CEO/CMO of 4Moving Biotech, Professor of rheumatology at Sorbonne University and Head of rheumatology department at St-Antoine’s hospital (AP-HP) in Paris “Through the development of this drug, we hope to bring a unique first-in-class solution to improve quality of life for the millions of people suffering from OA worldwide.”
The LASARE phase I clinical trial study is a randomized, double-blinded, controlled study to assess the safety and tolerability of a single ascending dose of liraglutide in adult patients between 18 and 80 years old with OA.
The trial is taking place in Belgium, conducted by the CRO, Artialis. It will aim to recruit 32 patients. Initial results are expected in Q1 2023.
